Slingshot members are tracking this event:

Galapagos (GLPG) reports top line results in the Phase 2a NOVESA trial with investigational ziritaxestat (GLPG1690) in patients with diffuse cutaneous systemic sclerosis (dcSSc), a severe autoimmune disease.

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details NOVESA is a double-blind, placebo-controlled Phase 2a proof-of-concept trial evaluating the efficacy, safety and tolerability of ziritaxestat (GLPG1690) in 33 patients with dcSSc. DcSSc is a severe autoimmune disease with one of the highest mortality rates among rheumatic diseases2 with no drugs currently approved to treat the overall disease. Systemic sclerosis (SSc) affects approximately 124,000 people3 in the US and Europe4, with a predominance of female patients (>80%).Patients recruited for NOVESA included mostly females (70%) around 50 years old, with a mean disease duration of 1.9 years. Most patients enrolled were on a background immunosuppressant therapy during the course of the study.Ziritaxestat was generally well tolerated. No deaths were reported in this study. Two patients taking ziritaxestat experienced serious adverse events versus one patient in the placebo group. Both patients in the ziritaxestat group recovered fully and are still participating in the long-term extension trial.94% of patients (31 of the 33) who completed the NOVESA trial continued in the long-term open label extension trial.“We are excited to see that after showing promising activity in the phase 2 FLORA trial in idiopathic pulmonary fibrosis, ziritaxestat achieved statistically significant improvements in mRSS in diffuse SSc, the primary endpoint in the NOVESA study. Keeping in mind that this is our first study in SSc and that the impact on skin is difficult to measure on a background treatment with immunosuppressants, we are pleased with the results reported today. We will now further analyze the NOVESA data to determine next steps in SSc, a disease with important unmet medical need,” said Dr Walid Abi-Saab, Chief Medical Officer of Galapagos.Detailed results from the NOVESA trial will be presented at future medical conferences.Ziritaxestat is an investigational drug and not approved by any regulatory authority. Its efficacy and safety have not been established.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 11, 2020
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ziritaxestat, Novesa, Systemic Sclerosis, Glpg1690, Diffuse Cutaneous Systemic Sclerosis, Dcssc, Autoimmune Diseases